Literature DB >> 16143707

Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients.

Karen Sliwa1, Olaf Förster, Elena Libhaber, James D Fett, Jay Bruce Sundstrom, Denise Hilfiker-Kleiner, Aftab A Ansari.   

Abstract

AIMS: Peripartum cardiomyopathy (PPCM) is a disorder of unknown aetiology with a course and outcome that is largely unpredictable. We evaluated the prognostic role of multiple inflammatory markers in the plasma of a large cohort of African patients with PPCM. METHODS AND
RESULTS: The study of 100 patients with newly diagnosed PPCM was single-centred, prospective, and longitudinal. Clinical assessment, echocardiography, and blood analysis were done at baseline and after 6 months of standard therapy. Inflammatory markers were measured at baseline only. Fifteen patients died. Left ventricular ejection fraction (LVEF) improved from 26.2+/-8.2 to 42.9+/-13.6% at 6 months (P<0.0001). However, normalization of LVEF (>50%) was only observed in 23%. Baseline levels of C-reactive protein correlated positively with baseline LV end-diastolic (rs=0.33, P=0.0026) and end-systolic (rs=0.35, P=0.0012) diameters and inversely with LVEF (rs=-0.27, P=0.015). Patients who died presented with significantly lower mean EF and higher Fas/Apo-1 plasma values (P<0.05). Fas/Apo-1 and New York Heart Association functional class (NYHA FC) predicted mortality at baseline.
CONCLUSION: Plasma markers of inflammation were significantly elevated and correlated with increased LV dimensions and lower LVEF at presentation. Baseline Fas/Apo-1 and higher NYHA FC were the only predictors of mortality. Normalization of LVEF was only observed in 23% of this African cohort.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16143707     DOI: 10.1093/eurheartj/ehi481

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  67 in total

Review 1.  16-kDa prolactin and bromocriptine in postpartum cardiomyopathy.

Authors:  Denise Hilfiker-Kleiner; Ingrid Struman; Melanie Hoch; Edith Podewski; Karen Sliwa
Journal:  Curr Heart Fail Rep       Date:  2012-09

Review 2.  Pathophysiology and epidemiology of peripartum cardiomyopathy.

Authors:  Denise Hilfiker-Kleiner; Karen Sliwa
Journal:  Nat Rev Cardiol       Date:  2014-04-01       Impact factor: 32.419

3.  African-American women have a higher risk for developing peripartum cardiomyopathy.

Authors:  Mindy B Gentry; James K Dias; Antonio Luis; Rakesh Patel; John Thornton; Guy L Reed
Journal:  J Am Coll Cardiol       Date:  2010-02-16       Impact factor: 24.094

4.  Value of the neutrophil-to-lymphocyte ratio in predicting left ventricular recovery in patients with peripartum cardiomyopathy.

Authors:  Ufuk Gürkan; Haldun Akgöz; Şukru Aksoy; Özlem Can Gürkan; Altug Osken; Sennur Unal Dayi; Dilaver Oz; Recep Haci
Journal:  Wien Klin Wochenschr       Date:  2017-07-12       Impact factor: 1.704

Review 5.  The Role of Cardiac Biomarkers in Pregnancy.

Authors:  Emily S Lau; Amy Sarma
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-07

Review 6.  Forgotten cardiovascular diseases in Africa.

Authors:  Karen Sliwa; Ana Olga Mocumbi
Journal:  Clin Res Cardiol       Date:  2009-12-11       Impact factor: 5.460

7.  [Peripartum cardiomyopathy: interdisciplinary challenge].

Authors:  B Löser; S Tank; G Hillebrand; B Goldmann; W Diehl; D Biermann; J Schirmer; D A Reuter
Journal:  Anaesthesist       Date:  2013-05       Impact factor: 1.041

Review 8.  Hypertension and hypertensive heart disease in African women.

Authors:  Karen Sliwa; Dike Ojji; Katrin Bachelier; Michael Böhm; Albertino Damasceno; Simon Stewart
Journal:  Clin Res Cardiol       Date:  2014-01-28       Impact factor: 5.460

9.  Peripartum cardiomyopathy: an intriguing challenge. Case report with literature review.

Authors:  Roberto Cemin; Rajesh Janardhanan; Massimo Daves
Journal:  Curr Cardiol Rev       Date:  2009-11

Review 10.  Peripartum cardiomyopathy: review of the literature.

Authors:  Pradipta Bhakta; Binay K Biswas; Basudeb Banerjee
Journal:  Yonsei Med J       Date:  2007-10-31       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.